Perkins S W, Sklarew E C
Indiana University Medical Center, Indianapolis, USA.
Plast Reconstr Surg. 1996 Sep;98(3):427-33; discussion 434-5. doi: 10.1097/00006534-199609000-00007.
A proposed clinical strategy is offered for the prevention and treatment of facial herpetic infection associated with phenol chemical peel or dermabrasion of the perioral area. A retrospective evaluation of 181 consecutive patients undergoing perioral chemical peel or dermabrasion from 1983 to 1990 was performed. No patients were excluded and the minimum follow-up was 6 to 24 months. All procedures were done at a private practice ambulatory surgery center. Patients with any history of oral herpetic lesions were pretreated with oral acyclovir. The vast majority of these patients received dosages far exceeding previously described regiments. A subset of patients (n = 12) whose procedures predated acyclovir's commercial availability received no prophylactic treatment and allowed for a comparison group. The incidence of postoperative infection was measured to determine the effectiveness of prophylactic acyclovir treatment. In patients reporting previous herpetic infection, postoperative herpetic outbreaks were far more likely to occur (50 percent infection rate) in the absence of prophylactic acyclovir. An 8.3 percent infection rate was noted in patients with a similar history who received standard acyclovir prophylaxis. Once high dose prophylactic treatment was initiated, no further herpetic outbreaks were observed. Even among patients with a negative history of oral herpes (no treatment), 6.6 percent developed postoperative infections. Pretreatment with high dose acyclovir clinically minimizes the incidence and severity of postoperative herpetic infection in patients undergoing perioral chemical peel or dermabrasion. All patients should be treated preoperatively with acyclovir regardless of past history, because even those patients reporting no previous outbreaks of oral herpes may develop postoperative infections.
本文提出了一种针对与苯酚化学剥脱术或口周区域磨皮术相关的面部疱疹感染的预防和治疗临床策略。对1983年至1990年间连续181例行口周化学剥脱术或磨皮术的患者进行了回顾性评估。无患者被排除,最短随访时间为6至24个月。所有手术均在一家私人门诊手术中心进行。有任何口腔疱疹病变病史的患者均口服阿昔洛韦进行预处理。这些患者中的绝大多数所接受的剂量远远超过先前描述的方案。一部分手术时间早于阿昔洛韦上市的患者(n = 12)未接受预防性治疗,作为对照组。通过测量术后感染发生率来确定预防性阿昔洛韦治疗的有效性。在报告有既往疱疹感染的患者中,在未使用预防性阿昔洛韦的情况下,术后疱疹复发的可能性要大得多(感染率为50%)。在有类似病史且接受标准阿昔洛韦预防治疗的患者中,感染率为8.3%。一旦开始高剂量预防性治疗,未观察到进一步的疱疹复发。即使在无口腔疱疹病史(未治疗)的患者中,6.6%也发生了术后感染。术前使用高剂量阿昔洛韦在临床上可将接受口周化学剥脱术或磨皮术患者术后疱疹感染的发生率和严重程度降至最低。所有患者无论既往病史如何,术前均应使用阿昔洛韦治疗,因为即使那些报告既往无口腔疱疹发作的患者也可能发生术后感染。